Aug 23 (Reuters) - Eli Lilly's ( LLY ) treatment for

early Alzheimer's is expected to be blocked for use by Britain's

National Health Service (NHS), The Telegraph reported on Friday.

The drug donanemab would be rejected by the National

Institute for Health and Care Excellence (NICE), which decides

what drugs are available on the NHS, the newspaper reported

citing insiders.

(Reporting by Nilutpal Timsina in Bengaluru)